D 9120
Latest Information Update: 11 Sep 2002
Price :
$50 *
At a glance
- Originator Celltech R&D
- Class Anti-inflammatories
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration; Inflammatory bowel diseases
Most Recent Events
- 11 Sep 2002 Discontinued - Preclinical for Age-related macular degeneration in United Kingdom (unspecified route)
- 11 Sep 2002 Discontinued - Preclinical for Inflammatory bowel disease in United Kingdom (unspecified route)
- 20 Aug 2001 Preclinical development for Age-related macular degeneration in United Kingdom (Unknown route)